Omiloxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Omiloxetine
Omiloxetine.svg
Systematic (IUPAC) name
2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone
Clinical data
Legal status
?
Identifiers
CAS number 176894-09-0
ATC code None
PubChem CID 3047803
ChemSpider 2310120
UNII H8YI0SSF7B
ChEMBL CHEMBL2105290
Chemical data
Formula C27H25F2NO4 
Mol. mass 465.489 g/mol
Physical data
Density 1.3±0.1 g/cm³
Melt. point 228.65 °C (444 °F)
Boiling point 587.2 °C (1089 °F)
Solubility in water 0.0015 mg/mL (20 °C)

Omiloxetine (INN) was a selective serotonin reuptake inhibitor drug candidate that was under development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005.[1][2]

References[edit]

  1. ^ Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19. 
  2. ^ De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19.